Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21ClFN3O4S |
| Molecular Weight | 441.904 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(NC(=O)NC2=C(O)C(=C(Cl)C=C2)S(=O)(=O)[C@H]3CCCNC3)C=CC=C1F
InChI
InChIKey=NGYNBSHYFOFVLS-LBPRGKRZSA-N
InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1
| Molecular Formula | C19H21ClFN3O4S |
| Molecular Weight | 441.904 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Danixirin is a potent, competitive, selective and reversible antagonist of the chemokine receptor (CXCR2) (also known as interleukin 8B receptor). In preclinical models, danixirin blocked neutrophils chemotaxis in response to inflammation. The drug is being developed by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease, influenza, respiratory syncytial virus. In phase 2 clinical trials in patients with acute, uncomplicated influenza, danixirin was well tolerated and did not impede viral clearance.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:53:08 GMT 2025
by
admin
on
Mon Mar 31 19:53:08 GMT 2025
|
| Record UNII |
R318PGH5VP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
954126-98-8
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY | |||
|
C169874
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY | |||
|
9559
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY | |||
|
100000166272
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY | |||
|
R318PGH5VP
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY | |||
|
SUB180340
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY | |||
|
24780598
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY | |||
|
DB11922
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY | |||
|
CHEMBL3039531
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY | |||
|
YY-70
Created by
admin on Mon Mar 31 19:53:08 GMT 2025 , Edited by admin on Mon Mar 31 19:53:08 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
